文献速递肾小球疾病

SANCTUARY试验尿液生物标志物分析:IgA肾病病理生理与ravulizumab机制

Urinary Biomarker Analysis of the SANCTUARY Trial: Insights into IgA Nephropathy Pathophysiology and Ravulizumab Mechanism of Action.
PubMed 文献 · Clin J Am Soc Nephrol · 2026-10-22

本研究为2期SANCTUARY试验的探索性分析,纳入60例IgA肾病患者和25名健康供者,评估ravulizumab(C5抑制剂)对尿补体激活、炎症及肾小管损伤标志物的影响。结果显示ravulizumab较安慰剂显著降低sC5b-9/Cr、Ba/Cr、CD163/Cr和KIM-1/Cr,且持续至第50周。

要点

  • IgA肾病患者基线尿补体激活、炎症及肾小管损伤标志物均显著高于健康供者。
  • ravulizumab较安慰剂显著降低尿sC5b-9/Cr和Ba/Cr(第2、10、18、26周)及CD163/Cr和KIM-1/Cr(第10、18、26周)。
  • 标志物降低持续至第50周,且安慰剂交叉至ravulizumab后也观察到降低。

核心结论

  • ravulizumab可早期、持续且显著降低IgA肾病患者尿补体激活标志物,并减少肾脏炎症和近端肾小管损伤标志物,与其降低蛋白尿的效应一致。

研究设计与样本

  • 探索性分析纳入2期SANCTUARY试验(NCT04564339)的60例IgA肾病患者和25名健康供者。
  • 收集第1、15、71、127、183天及之后每8周给药前点尿样本,检测补体激活(sC5b-9、Ba)、炎症(CD163)和肾小管损伤(KIM-1、NGAL)标志物,以肌酐正常化。
  • 按基线24小时尿蛋白(1-2 vs >2 g/day)和eGFR(30-60 vs ≥60-90 vs ≥90 mL/min/1.73 m2)分层比较,采用重复测量混合模型(MMRM)比较ravulizumab与安慰剂组。

主要发现

  • 基线时IgA肾病患者尿sC5b-9/Cr、Ba/Cr、CD163/Cr和KIM-1/Cr均显著高于健康供者(P < 0.001),93%患者sC5b-9/Cr升高。
  • 基线尿蛋白>2 g/day者sC5b-9/Cr、CD163/Cr和KIM-1/Cr显著高于1-2 g/day者(P < 0.05)。
  • 基线eGFR 30-60 mL/min/1.73 m2者sC5b-9/Cr和Ba/Cr最高(亚组间P < 0.05)。
  • ravulizumab组较安慰剂组在第2、10、18、26周sC5b-9/Cr和Ba/Cr显著降低,在第10、18、26周CD163/Cr和KIM-1/Cr显著降低(MMRM;P < 0.05)。
  • 这些标志物的降低持续至第50周,且安慰剂组在第26周交叉至ravulizumab后也观察到降低。

临床怎么用

  • 尿补体激活和肾小管损伤标志物可用于监测IgA肾病患者对C5抑制剂的早期治疗反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Complement activation in IgA nephropathy (IgAN) drives inflammation, nephron loss, and progressive kidney damage. We evaluated urinary biomarkers among participants with IgAN treated with ravulizumab (terminal complement C5 inhibitor) versus placebo in the Phase 2 SANCTUARY trial and healthy donors. METHODS: This exploratory analysis evaluated data from 60 participants with IgAN from SANCTUARY (NCT04564339) and 25 healthy donors. Spot urine samples were collected pre-dose on days 1, 15, 71, 127, and 183, and thereafter Q8W. Urinary biomarkers of complement activation (soluble C5b-9 [sC5b-9] and factor Ba), renal inflammation (CD163), and tubular injury (KIM-1, NGAL) were assessed, normalized to creatinine. Biomarkers were compared between subgroups: baseline 24-hour urine protein (1-2 vs >2 g/day) and eGFR (30-60 vs ≥60-90 vs ≥90 mL/min/1.73 m2). Ravulizumab and placebo groups were compared using mixed model for repeated measures (MMRM). RESULTS: Baseline levels of sC5b-9/Cr, Ba/Cr, CD163/Cr, and KIM-1/Cr were significantly elevated in participants with IgAN versus healthy donors (P < 0.001 for all); 93% participants had elevated sC5b-9/Cr. Baseline sC5b-9/Cr, CD163/Cr, and KIM-1/Cr were significantly higher in participants with baseline urine protein >2 g/day versus 1-2 g/day (P < 0.05 for all). Baseline sC5b-9/Cr and Ba/Cr were highest in participants with eGFR 30-60 mL/min/1.73 m2 (P < 0.05 across subgroups). Significantly greater reductions in sC5b-9/Cr and Ba/Cr were observed with ravulizumab versus placebo at Weeks 2, 10, 18, and 26; in CD163/Cr and KIM-1/Cr at Weeks 10, 18, and 26 (MMRM; P < 0.05 for all). Reductions in these biomarkers were sustained through Week 50 and were observed after crossover from placebo to ravulizumab at Week 26. CONCLUSIONS: Ravulizumab led to early, sustained, and significant reductions in urinary biomarkers of complement activation and decreases in markers of renal inflammation and proximal tubular injury; this is consistent with its observed effect on proteinuria.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Cammett TJ, Millman EE, Luna J, et al. Urinary Biomarker Analysis of the SANCTUARY Trial: Insights into IgA Nephropathy Pathophysiology and Ravulizumab Mechanism of Action. Clin J Am Soc Nephrol. 2026. PMID: 42912895. doi:10.2215/CJN.0000001243

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。